<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPLs) are associated with vascular occlusive events </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) and anticardiolipin antibody (aCL) are two aPLs commonly used for screening test </plain></SENT>
<SENT sid="2" pm="."><plain>However, other aPLs are reported to play a role in the thrombotic events in other disorders, especially <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated the clinical significance of the anti-annexin V antibody (aAV) in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>; annexin V promotes <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity via inhibition of prothrombin activation </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A total of 187 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, and 66 control subjects were included in this prospective study </plain></SENT>
<SENT sid="5" pm="."><plain>IgG type aAV was determined by enzyme-linked immunosorbent sandwich assay in the patient and control groups </plain></SENT>
<SENT sid="6" pm="."><plain>The presence of LA and aCL were determined in the patient group using the usual screening method </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: IgG aAV was detected in 26 of the 187 patients (13.9%), but only in three of the 66 control subjects (4.5%; P=0.043) </plain></SENT>
<SENT sid="8" pm="."><plain>Among the 26 aAV positive patients, only five patients were positive for LA or aCL </plain></SENT>
<SENT sid="9" pm="."><plain>The presence of IgG aAV was significantly associated with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>: one <z:hpo ids='HP_0001297'>stroke</z:hpo> event (OR, 4.39; 95% CI, 1.21-16.01), and two or more <z:hpo ids='HP_0001297'>stroke</z:hpo> events (OR, 3.91; 95% CI, 1.09-14.07) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: IgG aAV was detected in a significant percentage of the patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> compared with the control group </plain></SENT>
<SENT sid="11" pm="."><plain>The presence of IgG aAV did not usually coincide with LA or aCL </plain></SENT>
<SENT sid="12" pm="."><plain>Thus aAV should be considered as a possible associated factor for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>